Cobimetinib is a highly selective MEK1 inhibitor studied as a targeted therapy in BRAF and NRAS mutant melanoma [15], and it has been tested in preclinical studies in NRAS mutant AML [16]. This evidence concerns the gene NRAS and melanoma.